Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 19

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 19
---
 small molecule
    radiation sensitizers and immune activation candidates discovered and developed by Shuttle Pharma in cell-based and animal xenograft
    models.

    ○
    In
    conjunction with the Research Agreement, Shuttle Pharma also entered into a material transfer agreement (the “MTA”),
    dated March 21, 2023, with Georgetown University. Under the MTA, Shuttle Pharma agreed to transfer research quantities of candidate
    drug molecules to Georgetown University, which materials will be used by Georgetown University solely to carry out additional research
    for Shuttle Pharma and which materials shall at all times remain the property of Shuttle Pharma.

    ●
    Brown
    University

    ○
    Sub-contractor
    of the SBIR supported Phase I clinical trial of IPdR and RT (completed).

    ●
    University
    of Virginia

    ○
    Research
    collaboration to develop heavy oxygen molecules for proton radiation sensitizer applications.

    ●
    George
    Washington University

    ○
    Material
    transfer agreement for testing HDAC inhibitor effects in immune model systems.

    ○
    The
    material transfer agreement that protects our HDAC inhibitor intellectual property is with George Washington University, transferring
    drugs for research purposes and sharing authorship on publications. There is no transfer of funds related to such activities.

    ●
    Propagenix,
    Inc.

    ○
    License
    agreement for “conditional re-programmed cell” (CRC) technology. The cells established by Shuttle Pharma scientists at
    Georgetown University belong to us, based on the sublicense from Propagenix, Inc. An up-front licensing fee of $25,000 was paid to
    Propagenix. No other future milestone or royalty payments owed related to the Propagenix agreement.

14

Competition
“Off-Label” Use

Drugs
with radiation sensitizing properties.

Our
Product Candidates

We
are advancing a clinical stage product candidate, Ropidoxuridine, that we believe will target cancer cells while protecting healthy tissue
when used in conjunction with RT.

Ropidoxuridine

Ropidoxuridine,
an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, is our lead “clinical phase”
product candidate. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the
effects of RT. We have received an SBIR contract from the NIH